Clinical predictors of long-term efficacy of first-line pembrolizumab monotherapy in non-small cell lung cancer (NSCLC): an interim analysis of real-world data

被引：0

作者：

Younan, Helen-Cara ^{[1
]}

Zhang, Shuai ^{[2
]}

Monroy, Maria ^{[3
]}

Almusarhed, Manar ^{[4
]}

Julve, Max ^{[5
]}

Roy, Debashree ^{[4
]}

Toghey, Sopozme ^{[2
]}

Ahmed, Zartaj ^{[2
]}

Slater, Stephanie ^{[5
]}

Altharwane, Shaymaa ^{[4
]}

Giorgiou, Alex ^{[3
]}

Ghosh, Sharmistha ^{[3
]}

Gennatas, Spyridon ^{[3
]}

Karapanagiotou, Eleni ^{[3
]}

Montes, Ana ^{[3
]}

Pintus, Elias ^{[3
]}

Spicer, James ^{[3
]}

Shah, Riyaz ^{[2
]}

Ahmed, Samreen ^{[4
]}

Newsom-Davis, Tom ^{[5
]}

Mohammed, Waleed ^{[1
]}

Power, Danielle ^{[1
]}

Evans, Joanne ^{[1
]}

Hatcher, Olivia ^{[1
]}

Lakhani, Amish ^{[1
]}

Samani, Amit ^{[1
]}

Josephs, Debra ^{[3
]}

机构：

[1] Imperial Coll Healthcare NHS Trust, London, England

[2] Maidstone & Tunbridge Wells NHS Trust, Tunbridge Wells, Kent, England

[3] Guys & St Thomas NHS Fdn Trust, London, England

[4] Univ Hosp Leicester NHS Trust, Leicester, Leics, England

[5] Chelsea & Westminster Hosp NHS Fdn Trust, London, England

来源：

LUNG CANCER | 2022年 / 165卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S32 / S32

页数：1

共 50 条

[31] Keeping it real: implications of real-world treatment outcomes for first-line immunotherapy in metastatic non-small cell lung cancer
Hsu, Grace G.
MacKay, Eric
Scheuer, Nicolas
Ramagopalan, Sreeram, V
IMMUNOTHERAPY, 2021, 13 (18) : 1453 - 1456
[32] Real-world clinical outcomes among patients with advanced non-small cell lung cancer who initiated first-line regimens
Nadler, Eric
Arondekar, Bhakti
Aguilar, Kathleen
Zhou, Jie
Chang, Jane
Zhang, Xinke
Pawar, Vivek
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[33] Real-world long-term survival outcomes of first-line immunotherapy- based regimens in advanced non- small cell lung cancer
Waterhouse, David
Ray, Saurabh
Betts, Keith A.
Gao, Sophie
Yuan, Yong
Sundar, Manasvi
Rui, Shumin
Stenehjem, David
CANCER RESEARCH, 2024, 84 (06)
[34] Real-world outcomes of pembrolizumab monotherapy in non-small cell lung cancer in Japan: A post-marketing surveillance
Yamamoto, Nobuyuki
Kamitani, Tetsu
Kanda, Kingo
Ito, Yuichiro
Hamada, Masahiro
Ozaki, Masahiko
Takeuchi, Noriko
Yamada, Tomoko
Kawano, Masaki
Maekawa, Shinichiroh
Kato, Terufumi
CANCER SCIENCE, 2022, 113 (09) : 3110 - 3119
[35] Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis
Ikezawa, Yasuyuki
Morita, Ryo
Mizugaki, Hidenori
Tateishi, Kazunari
Yokoo, Keiki
Sumi, Toshiyuki
Kikuchi, Hajime
Kitamura, Yasuo
Nakamura, Atsushi
Kobayashi, Maki
Aso, Mari
Kimura, Nozomu
Yoshiike, Fumiaki
Megumi, Furuta
Tanaka, Hisashi
Sekikawa, Motoki
Hachiya, Tsutomu
Nakamura, Keiichi
Hommura, Fumihiro
Sukoh, Noriaki
Ito, Kenichiro
Kikuchi, Takashi
Agatsuma, Toshihiko
Yokouchi, Hiroshi
CANCER MEDICINE, 2024, 13 (14):
[36] First-line pembrolizumab for lung cancer in a Spanish real-world study.
Burgos, Amparo
Calleja, Teresa
Ibanez, Cristina
Maria Valencia, Carmen
Orallo, Claudia
Carlos Titos, Jose
Conde, David
Diaz, Sacramento
Matilla, Belen
Lizeaga, Garbine
Sanchez, Carmen
Marin Pozo, Juan Francisco
Jimenez, Silvia
Jimenez, Inmaculada
Diez, Raul
Garrido, Margarita
Larrosa, Maria
Jose Martinez, Maria
Moreno, Estela
Garcia Campelo, Rosario
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[37] Safety of pembrolizumab in patients with non-small cell lung cancer: a real-world study
Thakrar, D. B.
Essang, B.
Echlin, A.
Murdock, C.
Lind, M. J.
LUNG CANCER, 2019, 127 : S40 - S41
[38] Clinical and genomic characteristics of advanced non-small cell lung cancer (aNSCLC) patients (pts) with long-term response to first-line (1L) immunotherapy: A real-world study
Daher, S.
Shalata, W.
Biras, L.
Zer, A.
Shirron, N.
Goshen-Lago, T. G.
Dudnik, Y.
Cohen, A. Y.
Yaakobson, A.
Urban, D.
Sorotsky, H. Gantz
Shamai, S.
Lobachov, A.
Kutiel, T. Shentzer
Moskovitz, M. T.
Bar, J.
ANNALS OF ONCOLOGY, 2024, 35 : S843 - S843
[39] Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer
Waterhouse, David
Lam, Jenny
Betts, Keith A.
Yin, Lei
Gao, Sophie
Yuan, Yong
Hartman, John
Rao, Sumati
Lubinga, Solomon
Stenehjem, David
LUNG CANCER, 2021, 156 : 41 - 49
[40] Atezolizumab in first-line treatment of metastatic nonsquamous non-small cell lung cancer in the real-world setting.
De Castro, Javier
Campos Balea, Begona
Perez Parente, Diego
Polito, Letizia
Lawrance, Marcus
Ruiz Gracia, Pedro
Adler, Leah
Marina Arroyo, Marta
Socinski, Mark A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →